Verizon Business to transform Astellas Pharma’s global network infra
Digital transformation is seen as critical enabler in delivering improved patient outcomes and future growth
Verizon Business has been selected to manage Astellas Pharma’s (Astellas) global network infrastructure. The network transformation will enable Astellas to harness advanced technologies to help reduce drug development timelines, and healthcare costs and drive new revenue opportunities for the Japanese pharmaceutical multinational.
Headquartered in Tokyo, Japan, Astellas is a global pharmaceutical company involved in the research, development, manufacture, and marketing of innovative new drugs under the vision of “Stand on the forefront of healthcare change to turn innovative science into VALUE for patients”. The company employs 14,000 employees worldwide.
The company has identified digital transformation as a key driver of its business growth and began the search for a global partner to transform all aspects of its global technology infrastructure including building, designing and executing a next-generation secure network. In particular, Astellas was looking for a scalable and predictable platform that could seamlessly manage tens of thousands of devices and endpoints across Astellas’ 70+ global locations across a virtualised multi-sourced environment.
Verizon’s relationship with Astellas stretches back more than a decade. In 2016, Astellas successfully deployed Verizon’s Secure Cloud Interconnect (SCI) solution to provide a high-bandwidth secure connection to its Amazon Web Services (AWS) and Microsoft Azure cloud services. Verizon’s current remit includes the build and deployment of Astellas’ global integrated network with a full suite of managed services, including Managed Wide Area Network, Local Area Network, Managed Security Services (MSS), Secure Gateway, Zero Trust Network Access and Unified Communications and Collaboration as a Service.
Shinya Suda, Senior Vice President, Information Systems, Astellas commented, “From R&D to sales, we are seeing enormous amounts of data and intelligence flow through our business, across our 70 locations around the world. We want to ensure that we have a future-proof network to utilise cutting-edge technologies such as Artificial Intelligence, machine learning and robotics to make data-driven decisions to deliver better value for our patients. Our network transformation will underpin the next phase of our growth.”
“The network is transformative in its ability to enable innovation and growth and Astellas is changing the way they are using the tools at their disposal to completely revolutionise their business. This is truly a watershed moment for the pharmaceutical industry as companies grapple with the pressures of reducing time and costs for the development of drugs while improving patient care and value. We’re proud to have been a part of Astellas’ growth journey for more than a decade,” said Robert Le Busque, Regional Vice-President, Verizon Business Group, Asia Pacific.